{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:39:01Z","timestamp":1786444741929,"version":"build-2736575974"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T00:00:00Z","timestamp":1779840000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eye"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1038\/s41433-026-04566-2","type":"journal-article","created":{"date-parts":[[2026,5,27]],"date-time":"2026-05-27T14:39:15Z","timestamp":1779892755000},"page":"1860-1869","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Ocular involvement in toxic epidermal necrolysis syndrome at Chelsea and Westminster Hospital: a 10-year retrospective analysis and review of current literature"],"prefix":"10.1038","volume":"40","author":[{"given":"A.","family":"Pandey","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"O.","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Scawn","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"D.","family":"Collins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"Leon-Villapalos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5177-3180","authenticated-orcid":false,"given":"M.","family":"Sobti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,27]]},"reference":[{"key":"4566_CR1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.651247","volume":"8","author":"M Ueta","year":"2021","unstructured":"Ueta M. Pathogenesis of Stevens-Johnson syndrome\/toxic epidermal necrolysis with severe ocular complications. Front Med. 2021;8:651247.","journal-title":"Front Med"},{"key":"4566_CR2","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.ajo.2023.07.026","volume":"256","author":"XM Mortensen","year":"2023","unstructured":"Mortensen XM, Shenkute NT, Zhang AY, Banna H. Clinical outcome of amniotic membrane transplant in ocular Stevens-Johnson syndrome\/toxic epidermal necrolysis at a major burn unit. Am J Ophthalmol. 2023;256:80\u20139.","journal-title":"Am J Ophthalmol"},{"key":"4566_CR3","doi-asserted-by":"crossref","unstructured":"Shanbhag SS, Chodosh J, Fathy C, Goverman J, Mitchell C, Saeed HN. Multidisciplinary care in Stevens-Johnson syndrome. Ther Adv Chronic Dis. 2020;11:2040622319894469.","DOI":"10.1177\/2040622319894469"},{"key":"4566_CR4","doi-asserted-by":"publisher","first-page":"389","DOI":"10.4103\/0378-6323.110749","volume":"79","author":"TK Patel","year":"2013","unstructured":"Patel TK, Barvaliya MJ, Sharma D, Tripathi C. A systematic review of the drug-induced Stevens-Johnson syndrome and toxic epidermal necrolysis in Indian population. Indian J Dermatol Venereol Leprol. 2013;79:389.","journal-title":"Indian J Dermatol Venereol Leprol"},{"key":"4566_CR5","doi-asserted-by":"publisher","first-page":"384","DOI":"10.1001\/jamadermatol.2022.6378","volume":"159","author":"EY Lee","year":"2023","unstructured":"Lee EY, Knox C, Phillips EJ. Worldwide prevalence of antibiotic-associated Stevens-Johnson syndrome and toxic epidermal necrolysis: a systematic review and meta-analysis. JAMA Dermatol. 2023;159:384\u201392.","journal-title":"JAMA Dermatol"},{"key":"4566_CR6","doi-asserted-by":"publisher","first-page":"1996","DOI":"10.1016\/S0140-6736(16)30378-6","volume":"390","author":"TA Duong","year":"2017","unstructured":"Duong TA, Valeyrie-Allanore L, Wolkenstein P, Chosidow O. Severe cutaneous adverse reactions to drugs. Lancet. 2017;390:1996\u20132011.","journal-title":"Lancet"},{"key":"4566_CR7","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1007\/s00347-021-01351-2","volume":"118","author":"A Chronopoulos","year":"2021","unstructured":"Chronopoulos A, Mockenhaupt M, Pleyer U. Ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. Ophthalmologe. 2021;118:519\u201332.","journal-title":"Ophthalmologe"},{"key":"4566_CR8","doi-asserted-by":"publisher","first-page":"1653","DOI":"10.1016\/j.ophtha.2016.04.041","volume":"123","author":"DG Gregory","year":"2016","unstructured":"Gregory DG. New grading system and treatment guidelines for the acute ocular manifestations of Stevens-Johnson syndrome. Ophthalmology. 2016;123:1653\u20138.","journal-title":"Ophthalmology"},{"key":"4566_CR9","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1007\/s40123-023-00725-w","volume":"12","author":"G T\u00f3th","year":"2023","unstructured":"T\u00f3th G, Luk\u00e1cs A, Schirra F, S\u00e1ndor GL, Killik P, Maneschg OA, et al. Ophthalmic aspects of Stevens-Johnson syndrome and toxic epidermal necrolysis: a narrative review. Ophthalmol Ther. 2023;12:1795\u2013811.","journal-title":"Ophthalmol Ther"},{"key":"4566_CR10","doi-asserted-by":"publisher","first-page":"1343","DOI":"10.1007\/s40123-024-00924-z","volume":"13","author":"G T\u00f3th","year":"2024","unstructured":"T\u00f3th G, Luk\u00e1cs A, Stachon T, Schirra F, S\u00e1ndor GL, Nagy ZZ, et al. Clinical characteristics and treatment of ophthalmic sequelae of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis at a tertiary eyecare centre in Hungary. Ophthalmol Ther. 2024;13:1343.","journal-title":"Ophthalmol Ther"},{"key":"4566_CR11","doi-asserted-by":"publisher","first-page":"184","DOI":"10.4103\/tjo.tjo_13_21","volume":"12","author":"T Pradeep","year":"2022","unstructured":"Pradeep T, Shetti S. Ocular manifestations in acute stage Stevens-Johnson syndrome\/toxic epidermal necrolysis - a retrospective study in a tertiary hospital in South India. Taiwan J Ophthalmol. 2022;12:184.","journal-title":"Taiwan J Ophthalmol"},{"key":"4566_CR12","doi-asserted-by":"publisher","first-page":"709","DOI":"10.4168\/aair.2019.11.5.709","volume":"11","author":"CS Park","year":"2019","unstructured":"Park CS, Kang DY, Kang MG, Kim S, Ye YM, Kim SH, et al. Severe cutaneous adverse reactions to antiepileptic drugs: a nationwide registry-based study in Korea. Allergy Asthma Immunol Res. 2019;11:709.","journal-title":"Allergy Asthma Immunol Res"},{"key":"4566_CR13","doi-asserted-by":"publisher","first-page":"484","DOI":"10.1016\/j.ophtha.2015.10.027","volume":"123","author":"N Sharma","year":"2016","unstructured":"Sharma N, Thenarasun SA, Kaur M, Pushker N, Khanna N, Agarwal T, et al. Adjuvant role of amniotic membrane transplantation in acute ocular Stevens-Johnson syndrome: a randomized control trial. Ophthalmology. 2016;123:484\u201391.","journal-title":"Ophthalmology"},{"key":"4566_CR14","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1016\/j.ophtha.2011.01.046","volume":"118","author":"DG Gregory","year":"2011","unstructured":"Gregory DG. Treatment of acute Stevens-Johnson syndrome and toxic epidermal necrolysis using amniotic membrane: a review of 10 consecutive cases. Ophthalmology. 2011;118:908\u201314.","journal-title":"Ophthalmology"},{"key":"4566_CR15","doi-asserted-by":"publisher","first-page":"331","DOI":"10.1016\/j.ajo.2019.07.006","volume":"208","author":"SS Shanbhag","year":"2019","unstructured":"Shanbhag SS, Rashad R, Chodosh J, Saeed HN. Long-term impact of a treatment protocol for acute ocular involvement in Stevens-Johnson syndrome\/toxic epidermal necrolysis. Am J Ophthalmol. 2019;208:331.","journal-title":"Am J Ophthalmol"},{"key":"4566_CR16","doi-asserted-by":"crossref","unstructured":"Yang Y, Fung SSM, Chew H, Mireskandari K, Ali A. Amniotic membrane transplantation for Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis: the Toronto experience. Brit J Ophthalmol. 2021;105:1238\u201343.","DOI":"10.1136\/bjophthalmol-2020-316056"},{"key":"4566_CR17","doi-asserted-by":"crossref","unstructured":"Shammas MC, Lai EC, Sarkar JS, Yang J, Starr CE, Sippel KC. Management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis utilizing amniotic membrane and topical corticosteroids. Am J Ophthalmol. 2010;149. Available from: https:\/\/pubmed.ncbi.nlm.nih.gov\/20005508\/.","DOI":"10.1016\/j.ajo.2009.08.040"},{"key":"4566_CR18","doi-asserted-by":"publisher","first-page":"1394","DOI":"10.1097\/ICO.0b013e31823d02a8","volume":"31","author":"M Hsu","year":"2012","unstructured":"Hsu M, Jayaram A, Verner R, Lin A, Bouchard C. Indications and outcomes of amniotic membrane transplantation in the management of acute Stevens-Johnson syndrome and toxic epidermal necrolysis: a case-control study. Cornea. 2012;31:1394\u2013402.","journal-title":"Cornea"},{"key":"4566_CR19","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1016\/j.jtos.2020.03.004","volume":"18","author":"SS Shanbhag","year":"2020","unstructured":"Shanbhag SS, Hall L, Chodosh J, Saeed HN. Long-term outcomes of amniotic membrane treatment in acute Stevens-Johnson syndrome\/toxic epidermal necrolysis. Ocul Surf. 2020;18:517.","journal-title":"Ocul Surf"},{"key":"4566_CR20","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1097\/ICO.0000000000002816","volume":"41","author":"S Sharma","year":"2022","unstructured":"Sharma S, Singh S, Basu S, Shanbhag SS. Chronic ocular sequelae and subsequent surgical interventions in Stevens-Johnson syndrome after amniotic membrane transplantation. Cornea. 2022;41:632\u20134.","journal-title":"Cornea"},{"key":"4566_CR21","doi-asserted-by":"publisher","first-page":"667","DOI":"10.5301\/ejo.5000434","volume":"24","author":"JS L\u00f3pez-Garc\u00eda","year":"2014","unstructured":"L\u00f3pez-Garc\u00eda JS, Rivas L, Garc\u00eda-Lozano I, Conesa E, Elosua I, Murube J. Amniotic membrane transplantation in acute toxic epidermal necrolysis: histopathologic changes and ocular surface features after 1-year follow-up. Eur J Ophthalmol. 2014;24:667\u201375.","journal-title":"Eur J Ophthalmol"},{"key":"4566_CR22","doi-asserted-by":"crossref","unstructured":"Kojima M, Mieno H, Ueta M, Nakata M, Teramukai S, Sunaga Y, et al. Improvement of the ocular prognosis of Stevens-Johnson syndrome\/toxic epidermal necrolysis: a national survey in Japan. Am J Ophthalmol. 2024;267:50\u201360.","DOI":"10.1016\/j.ajo.2024.05.011"},{"key":"4566_CR23","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2023.1189140","volume":"10","author":"M Ueta","year":"2023","unstructured":"Ueta M, Inoue C, Nakata M, Sotozono C, Kim MK, Wakamatsu T, et al. Severe ocular complications of SJS\/TEN and associations among pre-onset, acute, and chronic factors: a report from the international ophthalmology collaborative group. Front Med. 2023;10:1189140.","journal-title":"Front Med"},{"key":"4566_CR24","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ajo.2015.05.002","volume":"160","author":"C Sotozono","year":"2015","unstructured":"Sotozono C, Ueta M, Nakatani E, Kitami A, Watanabe H, Sueki H, et al. Predictive factors associated with acute ocular involvement in Stevens-Johnson syndrome and toxic epidermal necrolysis. Am J Ophthalmol. 2015;160:228\u201337.e2.","journal-title":"Am J Ophthalmol"},{"key":"4566_CR25","doi-asserted-by":"publisher","first-page":"1030","DOI":"10.1136\/bjo.2010.196295","volume":"95","author":"T Yagi","year":"2011","unstructured":"Yagi T, Sotozono C, Tanaka M, Fuwa M, Sekiyama E, Ueta M, et al. Cytokine storm arising on the ocular surface in a patient with Stevens - Johnson syndrome. Brit J Ophthalmol. 2011;95:1030\u20131.","journal-title":"Brit J Ophthalmol"},{"key":"4566_CR26","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.clindermatol.2020.06.016","volume":"38","author":"MH Noe","year":"2020","unstructured":"Noe MH, Micheletti RG. Diagnosis and management of Stevens-Johnson syndrome\/toxic epidermal necrolysis. Clin Dermatol. 2020;38:607\u201312.","journal-title":"Clin Dermatol"},{"key":"4566_CR27","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1111\/bjd.17627","volume":"181","author":"D Thorel","year":"2019","unstructured":"Thorel D, Delcampe A, Ingen-Housz-Oro S, Hajj C, Gabison E, Chosidow O, et al. Dark skin phototype is associated with more severe ocular complications of Stevens\u2013Johnson syndrome and toxic epidermal necrolysis. Brit J Dermatol. 2019;181:212\u20133. https:\/\/doi.org\/10.1111\/bjd.17627.","journal-title":"Brit J Dermatol"},{"key":"4566_CR28","doi-asserted-by":"publisher","first-page":"2928","DOI":"10.1038\/s41598-021-82400-3","volume":"11","author":"GF Butt","year":"2021","unstructured":"Butt GF, Hassan A, Wallace GR, Kinoshita S, Ahmad S, Ueta M, et al. Human leukocyte antigen B*0702 is protective against ocular Stevens\u2013Johnson syndrome\/toxic epidermal necrolysis in the UK population. Sci Rep. 2021;11:2928.","journal-title":"Sci Rep"},{"key":"4566_CR29","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1016\/j.jaip.2017.09.001","volume":"6","author":"HK Lee","year":"2018","unstructured":"Lee HK, Yoon KC, Seo KY, Ueta M, Kim MK. Chronic ocular complications of Stevens-Johnson syndrome associated with causative medications in Korea. J Allergy Clin Immunol Pract. 2018;6:700\u20132.e2.","journal-title":"J Allergy Clin Immunol Pract"},{"key":"4566_CR30","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.jtos.2021.04.009","volume":"21","author":"R Rashad","year":"2021","unstructured":"Rashad R, Shanbhag SS, Kwan J, Chodosh J, Saeed S, Saeed HN. Chronic ocular complications in lamotrigine vs. trimethoprim-sulfamethoxazole induced Stevens-Johnson syndrome\/toxic epidermal necrolysis: comparing ocular severity in lamotrigine vs. TMP\/SMX Induced SJS\/TEN. Ocular Surface. 2021;21:16\u20138.","journal-title":"Ocular Surface"},{"key":"4566_CR31","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1248\/bpb.b23-00595","volume":"47","author":"E Tsukagoshi","year":"2024","unstructured":"Tsukagoshi E, Nakamura R, Kaniwa N, Sai K, Kikura-Hanajiri R, Matsunaga K, et al. Clinical profiles of Japanese Patients with Stevens-Johnson Syndrome\/toxic epidermal necrolysis collected by a nationwide system from 2006 to 2023. Biol Pharm Bull. 2024;47:88\u201397.","journal-title":"Biol Pharm Bull"},{"key":"4566_CR32","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.657327","volume":"8","author":"C Sotozono","year":"2021","unstructured":"Sotozono C, Ueta M, Kinoshita S. Japan: diagnosis and management of Stevens-Johnson syndrome\/toxic epidermal necrolysis with severe ocular complications. Front Med. 2021;8:657327.","journal-title":"Front Med"},{"key":"4566_CR33","first-page":"157","volume":"145","author":"J Gueudry","year":"2009","unstructured":"Gueudry J, Roujeau JC, Binaghi M, Soubrane G, Muraine M. Risk factors for the development of ocular complications of Stevens-Johnson syndrome and toxic epidermal necrolysis. Arch Dermatol. 2009;145:157\u201362.","journal-title":"Arch Dermatol"},{"key":"4566_CR34","doi-asserted-by":"crossref","unstructured":"Morales ME, Purdue GF, Verity SM, Arnoldo BD, Blomquist PH. Ophthalmic manifestations of Stevens-Johnson syndrome and toxic epidermal necrolysis and relation to SCORTEN. Am J Ophthalmol. 2010;150:505\u201310.e1.","DOI":"10.1016\/j.ajo.2010.04.026"},{"key":"4566_CR35","doi-asserted-by":"crossref","unstructured":"Ma DHK, Tsai TY, Pan LY, Chen SY, Hsiao CH, Yeh LK, et al. Clinical aspects of Stevens-Johnson syndrome\/toxic epidermal necrolysis with severe ocular complications in Taiwan. Front Med. 2021;8:661891.","DOI":"10.3389\/fmed.2021.661891"},{"key":"4566_CR36","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1186\/s13023-020-01538-x","volume":"15","author":"D Thorel","year":"2020","unstructured":"Thorel D, Ingen-Housz-Oro S, Royer G, Delcampe A, Bellon N, Bodemer C, et al. Management of ocular involvement in the acute phase of Stevens-Johnson syndrome and toxic epidermal necrolysis: French national audit of practices, literature review, and consensus agreement. Orphanet J Rare Dis. 2020;15:259.","journal-title":"Orphanet J Rare Dis"},{"key":"4566_CR37","doi-asserted-by":"publisher","first-page":"685","DOI":"10.1016\/j.ophtha.2008.12.048","volume":"116","author":"C Sotozono","year":"2009","unstructured":"Sotozono C, Ueta M, Koizumi N, Inatomi T, Shirakata Y, Ikezawa Z, et al. Diagnosis and treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular complications. Ophthalmology. 2009;116:685\u201390.","journal-title":"Ophthalmology"},{"key":"4566_CR38","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1016\/j.ajo.2023.05.010","volume":"253","author":"K Matsumoto","year":"2023","unstructured":"Matsumoto K, Ueta M, Inatomi T, Fukuoka H, Mieno H, Tamagawa-Mineoka Risa, et al. Topical betamethasone treatment of Stevens-Johnson syndrome and toxic epidermal necrolysis with ocular involvement in the acute phase. Am J Ophthalmol. 2023;253:142\u201351.","journal-title":"Am J Ophthalmol"},{"key":"4566_CR39","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1111\/j.1398-9995.2006.01295.x","volume":"62","author":"LW Yip","year":"2007","unstructured":"Yip LW, Thong BY, Lim J, Tan AW, Wong HB, Handa S, et al. Ocular manifestations and complications of Stevens-Johnson syndrome and toxic epidermal necrolysis: an Asian series. Allergy. 2007;62:527\u201331.","journal-title":"Allergy"},{"key":"4566_CR40","doi-asserted-by":"crossref","unstructured":"Sharma N, Venugopal R, Nagpal R, Priyadarshini K, Verma K, Verma KK, et al. Evaluation of adjuvant role of topical cyclosporine 1% in acute Stevens-Johnson syndrome: a randomised control trial. Brit J Ophthalmol. 2024;109:10\u201314.","DOI":"10.1136\/bjo-2023-324901"},{"key":"4566_CR41","doi-asserted-by":"crossref","unstructured":"Araki Y, Sotozono C, Inatomi T, Ueta M, Yokoi N, Ueda E, et al. Successful treatment of Stevens-Johnson syndrome with steroid pulse therapy at disease onset. Am J Ophthalmol. 2009;147:1004\u201311.e1.","DOI":"10.1016\/j.ajo.2008.12.040"},{"key":"4566_CR42","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1016\/j.ajo.2021.06.015","volume":"231","author":"H Mieno","year":"2021","unstructured":"Mieno H, Ueta M, Kinoshita F, Teramukai S, Kinoshita S, Sotozono C. Corticosteroid pulse therapy for Stevens-Johnson syndrome and toxic epidermal necrolysis patients with acute ocular involvement. Am J Ophthalmol. 2021;231:194\u20139.","journal-title":"Am J Ophthalmol"},{"key":"4566_CR43","doi-asserted-by":"publisher","first-page":"331","DOI":"10.3341\/kjo.2013.27.5.331","volume":"27","author":"KH Kim","year":"2013","unstructured":"Kim KH, Park SW, Kim MK, Wee WR. Effect of age and early intervention with a systemic steroid, intravenous immunoglobulin or amniotic membrane transplantation on the ocular outcomes of patients with Stevens-Johnson syndrome. Korean J Ophthalmol. 2013;27:331.","journal-title":"Korean J Ophthalmol"},{"key":"4566_CR44","doi-asserted-by":"publisher","first-page":"254","DOI":"10.1016\/j.ophtha.2014.08.013","volume":"122","author":"DH Kim","year":"2015","unstructured":"Kim DH, Yoon KC, Seo KY, Lee HS, Yoon SC, Sotozono C, et al. The role of systemic immunomodulatory treatment and prognostic factors on chronic ocular complications in Stevens-Johnson syndrome. Ophthalmology. 2015;122:254\u201364.","journal-title":"Ophthalmology"},{"key":"4566_CR45","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1016\/S0161-6420(95)30811-1","volume":"102","author":"WJ Power","year":"1995","unstructured":"Power WJ, Ghoraishi M, Merayo-Lloves J, Neves RA, Foster CS. Analysis of the acute ophthalmic manifestations of the erythema multiforme\/Stevens-Johnson syndrome\/toxic epidermal necrolysis disease spectrum. Ophthalmology. 1995;102:1669\u201376.","journal-title":"Ophthalmology"},{"key":"4566_CR46","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1177\/2042098611404094","volume":"2","author":"JC Roujeau","year":"2011","unstructured":"Roujeau JC, Bastuji-Garin S. Systematic review of treatments for Stevens\u2013Johnson syndrome and toxic epidermal necrolysis using the SCORTEN score as a tool for evaluating mortality. Ther Adv Drug Saf. 2011;2:87.","journal-title":"Ther Adv Drug Saf"},{"key":"4566_CR47","doi-asserted-by":"publisher","first-page":"658","DOI":"10.5301\/ejo.5000923","volume":"27","author":"A Pinna","year":"2017","unstructured":"Pinna A, Nuvoli E, Blasetti F, Posadinu MA, Boscia F. Plasmapheresis, intravenous immunoglobulins, and autologous serum eyedrops in the acute eye complications of toxic epidermal necrolysis. Eur J Ophthalmol. 2017;27:658\u201363.","journal-title":"Eur J Ophthalmol"},{"key":"4566_CR48","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/sj.eye.6701653","volume":"19","author":"LW Yip","year":"2004","unstructured":"Yip LW, Thong BY, Tan AW, Khin LW, Chng HH, Heng WJ. High-dose intravenous immunoglobulin in the treatment of toxic epidermal necrolysis: a study of ocular benefits. Eye. 2004;19:846\u201353.","journal-title":"Eye"},{"key":"4566_CR49","first-page":"5403","volume":"64","author":"HS Ong","year":"2023","unstructured":"Ong HS, Foo V, Lee HY, Mehta JS. Acute and chronic ocular outcomes in Steven-Johnson syndrome\/toxic epidermal necrolysis patients treated with Oral Ciclosporin A versus Intravenous Immunoglobulin. Invest Ophthalmol Vis Sci. 2023;64:5403.","journal-title":"Invest Ophthalmol Vis Sci"}],"container-title":["Eye"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04566-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04566-2","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04566-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,11]],"date-time":"2026-08-11T10:22:06Z","timestamp":1786443726000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41433-026-04566-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,27]]},"references-count":49,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["4566"],"URL":"https:\/\/doi.org\/10.1038\/s41433-026-04566-2","relation":{},"ISSN":["0950-222X","1476-5454"],"issn-type":[{"value":"0950-222X","type":"print"},{"value":"1476-5454","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,27]]},"assertion":[{"value":"18 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 March 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 May 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 May 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}]}}